NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 203)
Posted On: 02/26/2018 5:34:56 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Global Licensing Agreement with Neutrisci International Inc. (TSX-V: NU) (OTCQB: NRXCF)
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning said it has entered an agreement with NeutriSci International Inc. (TSX-V: NU) (OTCQB: NRXCF) resulting in NeutriSci now having 100% ownership of Ambarii Trade Corporation. Lexaria has also granted to NeutriSci an Intellectual Property License and Supply Agreement for the manufacturing and sale of CBD based products. Per the License Agreement, NeutriSci will remain focused on the development and sales of its existing and pipeline products that include Lexaria’s technology for enhancing palatability and bioavailability of beneficial non-psychoactive cannabinoids. Lexaria will receive continuing royalty revenues from the sales generated by these products. In addition, Lexaria also announced the exercise of warrants and options previously granted. The company has received a total of 46,266 warrants for exercise with an exercise price of US$0.60. The company has also received for exercise 50,000 stock options with an exercise price of US$0.2273, resulting in total proceeds of $39,124.60. These securities have not been registered under the United States Securities Act of 1933, and may not be offered or sold in the United States.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning said it has entered an agreement with NeutriSci International Inc. (TSX-V: NU) (OTCQB: NRXCF) resulting in NeutriSci now having 100% ownership of Ambarii Trade Corporation. Lexaria has also granted to NeutriSci an Intellectual Property License and Supply Agreement for the manufacturing and sale of CBD based products. Per the License Agreement, NeutriSci will remain focused on the development and sales of its existing and pipeline products that include Lexaria’s technology for enhancing palatability and bioavailability of beneficial non-psychoactive cannabinoids. Lexaria will receive continuing royalty revenues from the sales generated by these products. In addition, Lexaria also announced the exercise of warrants and options previously granted. The company has received a total of 46,266 warrants for exercise with an exercise price of US$0.60. The company has also received for exercise 50,000 stock options with an exercise price of US$0.2273, resulting in total proceeds of $39,124.60. These securities have not been registered under the United States Securities Act of 1933, and may not be offered or sold in the United States.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼